Creso Pharma’s Halucenex engages HeteroGeneity ahead of US entry

By Trevor Hoey. Published at May 26, 2021, in ASX Biotechs

In an important commercial development, Creso Pharma Limited’s (ASX:CPH, FRA:1X8) target acquisition company Halucenex Life Sciences Inc. has entered into a consultancy agreement with leading US-based scientific consultancy HeteroGeneity, LLC to progress a US market entry strategy for the potential use and licensing of the company’s botanical psilocybin products and compounds.

The agreement will assist in commencing licensing discussions with large pharmaceutical groups ahead of phase II clinical trials, in management’s view, a key factor in establishing a considerable competitive advantage.

HeteroGeneity is a scientific management organisation based in Washington DC that provides strategic and technical assistance to clients conducting research, development and commercialisation of drugs, biologics and medical devices for the US and Canadian markets.

The group specialises in the regulation, policy and science of complex, heterogeneous mixtures, while also addressing novel use areas for traditional medicine practice and naturally of historically complex products.

HeteroGeneity is at the forefront of regulation in North America and has been instrumental in assisting a number of companies achieve New Drug Approval Applications through the Food and Drug Administration (FDA) for the US market.

Under the agreement, both parties will conduct a technology assessment to progress a development plan for a new botanical drug under pharmaceutical development for the US market.

This will include advisory around clinical indications, regulatory status of proposed ingredients, sourcing, manufacturing and formulation, compilation of supporting data and intellectual property considerations amongst other initiatives.

HeteroGeneity shall be compensated on an hourly basis, and may be terminated without cause by either party upon giving 30 days written notice.

Strategically important in entering US market

The agreement marks an important first step in the company’s US market entry strategy.

HeteroGeneity will assist Creso Pharma and Halucenex with any required FDA regulatory approvals, and will enable Creso to start discussions with large-scale pharmaceutical companies around licensing agreements for its extracts and psychedelic compounds.

Based on independent research, the psychedelic therapeutic drug market in the US is expected to reach a total value of US$6.7 billion by 2027, making it a very lucrative opportunity for Creso Pharma.

Ahead of the pending phase II clinical trial, Halucenex has assembled a market-leading team of consultants and strategic partners, providing the group with a considerable competitive advantage as it progresses clinical trials and positions for entry into the US market, subject to necessary legislative reform.

Creso Pharma sees the prospect of entering the US market as a very positive step, and on this note non-executive chairman Adam Blumenthal said, “Creso’s Board and management are very pleased that Halucenex is taking steps forward in the early stages to progress a US market entry.

“Having centralised operations in Nova Scotia will provide Halucenex with considerable advantages when undertaking the steps required to progress regulatory approvals and potential discussions with large pharmaceutical groups for the licensing of the group’s psilocybin extracts and compounds.”


View Our Investment Portfolios


S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X